Objective To study the role of serum resistin and high-sensitivity C-reactive protein (hs-CRP) in idiopathic sudden sensorineural hearing loss. Methods The levels resistin and hs-CRP were determined in the 102 idiopathic sudden sensorineural hearing loss patients who were observed at two differ-ent time points: before and after treatment, and 35 patients with other neurologic diseases and 30 healthy people were used as control. Results The levels resistin and hs-CRP in serum of patients with idiopathic sudden sensorineural hearing loss were markedly higher than those in the controls (P< 0.01). The levels of resistin and ha-CRP in the patients with idiopathic sudden sensorineural hearing loss after treatment were significantly less than those before treatment. There was a correlation between serum resistin and hs-CRP in patients with idiopathic sudden senserineural hearing loss (r=0.65, P<0.01). Conclusion The levels of serum resistin and hs-CRP have instructive significance in idiopathic sudden sensorineural hearing loss treating and prognosis estimating.

ObjectiveTo study the role and clinical significance of serum visfatin and retinol binding protein 4 (RBP4) in idiopathic sudden sensorineural hearing loss by measuring the change of their levels in the patients with idiopathic sudden sensorineural hearing loss.MethodsThe levels of visfatin and RBP4 were determined by ELISA method in the 102 idiopathic sudden sensorineural hearing loss patients who were observed at two different time points ( before and after treatment),and thirty-five patients with other neurologic diseases (20 with sciatica,16 with trigeminal neuralgia) and thirty healthy people were used as control.ResultsThe levels of visfatin and RBP4 in the serum of patients with idiopathic sudden sensorineural hearing loss after treatment [Visfatin (24.26 ± 2.17 ) μg/L; RBP4 (46.65± 5.26 ) mg/L]were markedly higher than the group with other neurologic diseases [Visfatin ( 20.67 ± 2.14 ) μ g/L; RBP4(34.37 ±5.73)mg/L] and the healthy control group[Visfatin(17.61 ±2.45) μg/L; RBP4 (24.82 ±5.24)mg/L] ( t =10.38,10.41,12.16,15.06,P ＜0.01),and it was significantly less than that before treatment [Visfatin(32.24 ± 2.37) μ /L; RBP4 ( 57.43 ± 6.19 ) mg/L] ( t =17.25,15.12,P ＜ 0.01 ).The levels visfatin and RBP4 in serum of severe group with idiopathic sudden sensorineural hearing loss [Visfatin ( 36.52 ± 2.46 ) μg/L; RBP4 (67.17 ± 5.92 ) mg/L] were markedly higher than those in the moderate group[Visfatin(28.92 ±2.26)μg/L; RBP4 (55.34±5.95)mg/L]( t =11.21,11.17,P ＜0.01).The levels visfatin and RBP4 in serum of moderate group were markedly higher than those in the mild group [Visfatin ( 25.31 ± 2.32 ) μg/L; RBP4 ( 47.48 ± 5.82 ) mg/L],all these differences were statistically significant( t =10.43,10.49,P ＜0.01 ).There was a positive correlation between visfatin and RBP4 in patients with idiopathic sudden sensorineural hearing loss ( r =0.68,P ＜ 0.01 ).ConclusionsThe levels of serum visfatin and RBP4 have instructive significance in idiopathic sudden sensorineural hearing loss treatingand prognosis estimating